Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Ingenia Elition 3.0T MR solution and two clinical applications, Philips Compressed SENSE and 3D APT. This integrated suite of innovations enables clinicians to perform exams up to 50% faster , increase diagnostic confidence and improve the patient experience. The first commercial installation of the Philips Ingenia Elition in the U.S. has recently been completed at Hennepin Healthcare, a comprehensive healthcare system in Minneapolis.
“Together, the Ingenia Elition and our new clinical applications make producing high-quality images fast and easy, enabling prompt diagnosis and setting the stage for effective treatment,” said Arjen Radder, Global Business Leader for MR at Philips. “We’re receiving a strong positive reaction from our customers as we continue to roll out our all-new Ingenia digital MR portfolio. It’s providing healthcare organizations like Hennepin Health with innovative solutions that seamlessly connect data, technology and people to drive the highest quality of care.”
In today’s healthcare landscape – where reimbursements are becoming value-based and chronic conditions lead to more MR procedures and longer waiting times – there is an ever-increasing pressure on the radiology department. Philips is responding to these challenges through the development of new systems and clinical applications that improve image quality and the patient and staff experience, as well as operational efficiency.